Figure 2.

Efficacy of CAN017 in large ESCC PDX models in cohort 1. A. Tumor growth curves showed the in vivo activity of 22 ESCC PDX models treated with vehicle control, hIgG control (20 mg/kg) and CAN017 (20 mg/kg) every 3 days. Data were expressed as means ± SDs for at less five mice in each group. The anti-tumor activity was depicted by TGI described in each picture. B. Waterfall plot displayed the different response to CAN017 of 24 PDX models in cohort 1. Dotted line indicated the TGI of 70%. C. Comparison of tumor growth inhibition between hIgG group and CAN017 group. ***P < 0.001 analyzed by unpaired two-tailed t test.